Search

Olga M Fryszman

age ~56

from San Diego, CA

Also known as:
  • Olga Fryszman
  • Olga N
  • Olga Insko
  • Olga Frysman
Phone and address:
11274 Ganesta Rd, San Diego, CA 92126

Olga Fryszman Phones & Addresses

  • 11274 Ganesta Rd, San Diego, CA 92126
  • 9361 Hillery Dr, San Diego, CA 92126
  • 4311 Casanna Way, Oceanside, CA 92057
  • 6208 Adobe Cir, Irvine, CA 92612
  • 3113 Verano Pl, Irvine, CA 92612
  • Princeton, NJ
  • Plainsboro, NJ
  • 9361 Hillery Dr Apt 20102, San Diego, CA 92126 • (858)2714397

Work

  • Position:
    Machine Operators, Assemblers, and Inspectors Occupations

Education

  • Degree:
    Bachelor's degree or higher

Us Patents

  • 5-Membered Heterocycle-Based P38 Kinase Inhibitors

    view source
  • US Patent:
    7863314, Jan 4, 2011
  • Filed:
    Jun 25, 2004
  • Appl. No.:
    10/877534
  • Inventors:
    Olga M. Fryszman - San Diego CA, US
    Hengyuan Lang - San Diego CA, US
    Jiong Lan - San Diego CA, US
    Edcon Chang - San Diego CA, US
    Yunfeng Fang - San Diego CA, US
  • Assignee:
    Novartis AG - Basel
  • International Classification:
    A01N 43/56
    C07D 231/00
  • US Classification:
    514407, 5483714
  • Abstract:
    Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
  • 5-Membered Heterocycle-Based P38 Kinase Inhibitors

    view source
  • US Patent:
    8242117, Aug 14, 2012
  • Filed:
    Nov 19, 2010
  • Appl. No.:
    12/950649
  • Inventors:
    Olga M. Fryszman - San Diego CA, US
    Hengyuan Lang - San Diego CA, US
    Jiong Lan - Emeryville CA, US
    Edcon Chang - San Diego CA, US
    Yunfeng Fang - San Diego CA, US
  • Assignee:
    Novartis AG - Basel
  • International Classification:
    A61K 31/5355
    A61K 31/415
    A61K 31/4164
    A61K 31/4245
    A61K 31/4439
    A61K 31/506
    A61K 31/497
    A61P 13/00
    A61P 9/00
    A61P 11/06
    A61P 25/28
    A61P 31/12
    A61P 1/00
  • US Classification:
    5142365, 51425405, 514256, 514341, 514364, 514386, 514407
  • Abstract:
    Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
  • 5-Membered Heterocycle-Based P38 Kinase Inhibitors

    view source
  • US Patent:
    8410160, Apr 2, 2013
  • Filed:
    Jun 22, 2012
  • Appl. No.:
    13/530919
  • Inventors:
    Olga M. Fryszman - San Diego CA, US
    Hengyuan Lang - San Diego CA, US
    Jiong Lan - Moraga CA, US
    Edcon Chang - San Diego CA, US
    Yunfeng Fang - San Diego CA, US
  • Assignee:
    Novartis AG - Basel
  • International Classification:
    A61K 31/415
    A61P 13/12
    A61P 9/00
    A61P 11/00
  • US Classification:
    514407
  • Abstract:
    Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α, and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
  • 5-Membered Heterocycle-Based P38 Kinase Inhibitors

    view source
  • US Patent:
    8580838, Nov 12, 2013
  • Filed:
    Feb 25, 2013
  • Appl. No.:
    13/775963
  • Inventors:
    - Basel, CH
    Olga M. Fryszman - San Diego CA, US
    Edcon Chang - San Diego CA, US
    Jiong Lan - Morago CA, US
    Yunfeng Fang - San Diego CA, US
  • Assignee:
    Novartis AG - Basel
  • International Classification:
    A61K 31/415
    A61P 13/12
    A61P 9/00
    A61P 11/00
  • US Classification:
    514407
  • Abstract:
    Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α, and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
  • .Alpha.-Phosphonosulfinic Squalene Synthetase Inhibitors

    view source
  • US Patent:
    54479223, Sep 5, 1995
  • Filed:
    Aug 24, 1994
  • Appl. No.:
    8/295121
  • Inventors:
    R. Michael Lawrence - Yardley PA
    Scott A. Biller - Ewing NJ
    Olga M. Fryszman - Princeton NJ
  • Assignee:
    Bristol-Myers Squibb Company - Princeton NJ
  • International Classification:
    A61K 3166
    C07F 938
    C07F 940
  • US Classification:
    514129
  • Abstract:
    alpha. -Phosphonosulfinate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R. sup. 2 is OR. sup. 5 or R. sup. 5a ; R. sup. 3 and R. sup. 5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R. sup. 5a is alkyl, arylalkyl or aryl; R. sup. 4 is H or pharmaceutically acceptable cation;, Z is H, halogen, lower alkyl or lower alkenyl; and R. sup. 1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts.
  • Methods Of Preparing .Alpha.-Phosphonosulfinate Squalene Synthetase Inhibitors

    view source
  • US Patent:
    55435424, Aug 6, 1996
  • Filed:
    May 22, 1995
  • Appl. No.:
    8/445604
  • Inventors:
    R. Michael Lawrence - Yardley PA
    Scott A. Biller - Ewing NJ
    Olga M. Fryszman - Princeton NJ
  • International Classification:
    C07F 938
    C07F 940
  • US Classification:
    558 87
  • Abstract:
    alpha. -Phosphonosulfinate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R. sup. 2 is OR. sup. 5 or R. sup. 5a ; R. sup. 3 and R. sup. 5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R. sup. 5a is alkyl, arylalkyl or aryl; R. sup. 4 is H or a pharmaceutically acceptable cation; Z is H, halogen, lower alkyl or lower alkenyl; and R. sup. 1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; including pharmaceutically acceptable salts.

Get Report for Olga M Fryszman from San Diego, CA, age ~56
Control profile